コンテンツへスキップ
Merck
  • [Allopurinol hypersensitivity syndrome: Liver transplantation after treatment of asymptomatic hyperuricaemia].

[Allopurinol hypersensitivity syndrome: Liver transplantation after treatment of asymptomatic hyperuricaemia].

Deutsche medizinische Wochenschrift (1946) (2014-11-26)
S E Miederer, K O Miederer
要旨

A 41 year old patient started treatment with 300 mg/d allopurinol for asymptomatic hyperuricaemia (9,2 mg/dl). 4 weeks later he developed exfoliative skin lesions with haemorrhage, fever, eosinophilia and acute liver and renal failure, typical for an allopurinol hypersensitivity syndrome (AHS).An orthotopic liver-transplantation was performed. The AHS is a serious iatrogenic disease. 2 % of the treated patients develop a skin rash. 0,4 % of these patients experience suddenly and unforeseen a severe hypersensitivity with a mortality of 14-30 %. An early diagnosis is often very difficult. In the pathogenesis different causes are discussed. A hereditary component is involved. Of essential importance is the amount of the starting dose, the kidney function and concomitant drugs. In an asymptomatic hyperuricaemia the application of allopurinol is not indicated. If strong indications are present, the allopurinol therapy has to start with the lowest dose (100 mg/d). If required this dose should be increased under consequent supervision only.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
アモキシシリン, 95.0-102.0% anhydrous basis
Sigma-Aldrich
アロプリノール, xanthine oxidase inhibitor
USP
アモキシシリン, United States Pharmacopeia (USP) Reference Standard
Supelco
アモキシシリン 三水和物, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
アモキシシリン 三水和物, VETRANAL®, analytical standard
Supelco
アロプリノール, Pharmaceutical Secondary Standard; Certified Reference Material
アモキシシリン 三水和物, European Pharmacopoeia (EP) Reference Standard
アモキシシリン 三水和物, European Pharmacopoeia (EP) Reference Standard
アロプリノール, European Pharmacopoeia (EP) Reference Standard